TG Therapeutics Ownership

TGTX Stock  USD 33.36  0.01  0.03%   
Over half of TG Therapeutics' outstanding shares are owned by institutions. These institutions are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions.
 
Shares in Circulation  
First Issued
1996-03-31
Previous Quarter
159.4 M
Current Value
160.7 M
Avarage Shares Outstanding
37.6 M
Quarterly Volatility
50.6 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Some institutional investors establish a significant position in stocks such as TG Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of TG Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TG Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.

TGTX Stock Ownership Analysis

About 67.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.1. TG Therapeutics had not issued any dividends in recent years. The entity had 100:5625 split on the 30th of April 2012. TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York. Tg Therapeuticscmn operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 173 people. To find out more about TG Therapeutics contact Michael Esq at 212 554 4484 or learn more at https://www.tgtherapeutics.com.

TGTX Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as TG Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading TG Therapeutics backward and forwards among themselves. TG Therapeutics' institutional investor refers to the entity that pools money to purchase TG Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Deep Track Capital, Lp2024-09-30
1.7 M
Bank Of America Corp2024-09-30
1.7 M
Hood River Capital Management Llc2024-09-30
1.6 M
Northern Trust Corp2024-09-30
1.4 M
Charles Schwab Investment Management Inc2024-09-30
1.2 M
Fmr Inc2024-09-30
1.2 M
683 Capital Management Llc2024-09-30
1.1 M
Two Sigma Investments Llc2024-09-30
1.1 M
Amvescap Plc.2024-09-30
918.8 K
Blackrock Inc2024-09-30
22 M
Vanguard Group Inc2024-09-30
15.4 M
Note, although TG Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

TG Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific TG Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on TG Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases TG Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

TG Therapeutics Outstanding Bonds

TG Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. TG Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most TGTX bonds can be classified according to their maturity, which is the date when TG Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

TG Therapeutics Corporate Filings

F4
30th of January 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
14th of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8th of January 2025
Other Reports
ViewVerify
13A
14th of November 2024
An amended filing to the original Schedule 13G
ViewVerify

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.